Sandbox malka: Difference between revisions
New page: The high affinity of the noncovalent interaction between biotin and streptavidin forms the basis for many diagnostic assays that require the formation of an irreversible and specific linka... |
Yael Shwartz (talk | contribs) No edit summary |
||
| (21 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
<scene name='Sandbox_malka/Hiv_ribbon_sheet/1'>sheet</scene> | |||
<scene name='Sandbox_malka/Hiv_ribbon_helix/5'>helix</scene> | |||
<scene name='Sandbox_malka/Hiv_ribbon_medicine/1'>drug</scene> | |||
<scene name='Sandbox_malka/Hiv_ribbon/3'>active site</scene> | |||
< | <scene name='Sandbox_malka/Hiv_ribbon_helix/6'>his</scene> | ||
<scene name='Sandbox_malka/Fgf9/2'>active sites in magenta</scene> | |||
<StructureSection load='2nmz' size='500' side='right' background='none' scene='User:David_Canner/Sandbox_HIV/Opening/2' caption='Structure of HIV Protease'> | |||
[[Image:CannergreyHIV2.png|220px|left]][[Human Immunodeficiency Virus]] (HIV) is the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV directs the synthesis of several polyproteins, which each consist of several tandemly linked proteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins. <scene name='User:David_Canner/Sandbox_HIV/Opening/2'>HIV-1 protease</scene>, a homodimeric enzyme, is responsible for doing so and is therefore crucial to the virus's infectious capacity. | |||
===Structure of HIV-1 Protease=== | |||
The X-ray structure of HIV-1 protease reveals that it is composed of <scene name='User:David_Canner/Sandbox_HIV/Identical_subunits/1'>two symmetrically related subunits</scene>, each consisting of 99 amino acid residues. The subunits come together in such as way as to <scene name='User:David_Canner/Sandbox_HIV/Tunnel/1'>form a tunnel where they meet</scene>. This tunnel is of critical importance because the active site of the protease is located in its interior. The active site consists of <scene name='User:David_Canner/Sandbox_HIV/Catalytic_triad/3'> two Asp-Thr-Gly conserved sequences</scene>, making it a member of the aspartyl protease family. The two Asp's are <scene name='User:David_Canner/Sandbox_HIV/Catalytic_asp/1'>essential catalytic residues</scene> that activate a water molecule to hydrolytically cleave the polyprotein that binds in the tunnel.<ref>PMID:1799632</ref> You may be wondering how a polyprotein makes its way into the active-site tunnel, as the<scene name='User:David_Canner/Sandbox_HIV/Narrow_tunnel/1'> tunnel appears to be too narrow </scene> to admit it. The key is the two flexible flaps on the top of the tunnel that <scene name='User:David_Canner/Sandbox_HIV/Hiv_tunnel_morph/3'>move to allow proteins </scene>to enter the tunnel. The flaps <scene name='User:David_Canner/Sandbox_HIV/Hiv_tunnel_morph_flaps/2'>undergo a dramatic movement</scene>, shifting from an open to a closed conformation to bind the target in an appropriate conformation for cleavage. | |||
===Medical Implications=== | |||
There currently is no cure or vaccine against HIV. Researchers, however, have discovered treatments that can halt and even reverse the progression of AIDS, due in large part to our understanding of the structure of HIV-1 protease. <scene name='User:David_Canner/Sandbox_HIV/Saquinavir/4'>Saquinavir</scene> ([[Invirase]]) was the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV protease by <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'>binding tightly in the active site tunnel</scene>, preventing the binding of polyproteins. Its chemical structure mimics the tetrahedral intermediate of the hydrolytic reaction, thereby <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'>interacting strongly with the catalytic Asp residues</scene>.<ref>PMID:17243183</ref> Saquinavir is essentially an uncleavable ligand, as indicated by the <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> similar conformational changes in the protease flaps </scene> on binding saquinavir or a polypeptide . Other drugs used to treat HIV infection that inhibit <scene name='User:David_Canner/Sandbox_HIV/Inhibitor_intro/1'>HIV protease</scene> include <scene name='User:David_Canner/Sandbox_HIV/Indinavir/2'>Indinavir </scene> ([[Crixivan]]), <scene name='User:David_Canner/Sandbox_HIV/Ritonavir/1'>Ritonavir</scene> ([[Norvir]]), and <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[Viracept]]). | |||
__NOEDITSECTION__ | |||
__NOTOC__ | |||
</StructureSection> | |||
==3D Structures of HIV-1 protease== | |||
# [[Virus protease]] | |||
==Additional Resources== | |||
For additional information, see: [[Human Immunodeficiency Virus]] | |||
<br /> | |||
* [http://www.rcsb.org/pdb/static.do?p=education_discussion/educational_resources/hiv-animation.html Structural Biology of HIV], an interactive Flash graphic of the virion with explanations of its components. | |||
==References== | |||
<references/> | |||
<scene name='Sandbox_malka/Hiv_ribbon_helix/3'>helix only</scene> | |||
Latest revision as of 15:03, 10 July 2011
 Human Immunodeficiency Virus (HIV) is the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV directs the synthesis of several polyproteins, which each consist of several tandemly linked proteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins. , a homodimeric enzyme, is responsible for doing so and is therefore crucial to the virus's infectious capacity. Structure of HIV-1 ProteaseThe X-ray structure of HIV-1 protease reveals that it is composed of , each consisting of 99 amino acid residues. The subunits come together in such as way as to . This tunnel is of critical importance because the active site of the protease is located in its interior. The active site consists of , making it a member of the aspartyl protease family. The two Asp's are that activate a water molecule to hydrolytically cleave the polyprotein that binds in the tunnel.[1] You may be wondering how a polyprotein makes its way into the active-site tunnel, as the to admit it. The key is the two flexible flaps on the top of the tunnel that to enter the tunnel. The flaps , shifting from an open to a closed conformation to bind the target in an appropriate conformation for cleavage. Medical ImplicationsThere currently is no cure or vaccine against HIV. Researchers, however, have discovered treatments that can halt and even reverse the progression of AIDS, due in large part to our understanding of the structure of HIV-1 protease. (Invirase) was the first protease inhibitor approved by the FDA for the treatment of HIV. It inhibits HIV protease by , preventing the binding of polyproteins. Its chemical structure mimics the tetrahedral intermediate of the hydrolytic reaction, thereby .[2] Saquinavir is essentially an uncleavable ligand, as indicated by the on binding saquinavir or a polypeptide . Other drugs used to treat HIV infection that inhibit include (Crixivan), (Norvir), and (Viracept).
|
| ||||||||||
3D Structures of HIV-1 protease3D Structures of HIV-1 protease
Additional ResourcesAdditional Resources
For additional information, see: Human Immunodeficiency Virus
- Structural Biology of HIV, an interactive Flash graphic of the virion with explanations of its components.
ReferencesReferences
- ↑ Spinelli S, Liu QZ, Alzari PM, Hirel PH, Poljak RJ. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie. 1991 Nov;73(11):1391-6. PMID:1799632
- ↑ Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins. 2007 Apr 1;67(1):232-42. PMID:17243183 doi:10.1002/prot.21304